Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole versus triptorelin for symptomatic uterine fibroids
IRCT20221108056446N10Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Fibromyoma (LM) comparing Letrozole arm with Triptorelin control arm (2 arms). Primary endpoint: Uterine fibroid size. Started Aug 2024; status: completed.
02
Drugs
letrozoletriptorelin
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20221108056446N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221108056446N10.